share_log

FSD Pharma (NASDAQ:HUGE) Shares Up 2.3%

Defense World ·  Sep 6, 2022 01:21

FSD Pharma Inc. (NASDAQ:HUGE – Get Rating)'s stock price shot up 2.3% on Monday . The stock traded as high as $0.89 and last traded at $0.89. 1,995 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 111,853 shares. The stock had previously closed at $0.87.

FSD Pharma Price Performance

The company's fifty day moving average is $0.93 and its two-hundred day moving average is $0.90.

Get FSD Pharma alerts:

Institutional Investors Weigh In On FSD Pharma

Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its position in FSD Pharma by 145.1% in the 1st quarter. Renaissance Technologies LLC now owns 32,600 shares of the company's stock worth $28,000 after purchasing an additional 19,300 shares in the last quarter. AdvisorShares Investments LLC purchased a new stake in FSD Pharma in the 1st quarter worth approximately $148,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in FSD Pharma in the 4th quarter worth approximately $1,007,000. Hedge funds and other institutional investors own 1.26% of the company's stock.

About FSD Pharma

(Get Rating)

FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Featured Articles

  • Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
  • What Does an Inverted Yield Curve Mean For You?
  • SPY vs. QQQ: Which ETF Wins in 2022?
  • Could Snap Stock Rebound As Management Restructures?
  • MarketBeat: Week in Review 8/29 – 9/2
  • Hormel Looks Cheap At These Levels

Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment